GlassScriptPhysician profile
Manouchehr Refaeian
NPI 1689632945
$8,603.07
in general payments reported to CMS, 2019-2025
24 companies · $5,370 in 2025
The $5,370 reported for 2025 was more than what 92% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $381 · 2021: $471 · 2022: $469 · 2023: $233 · 2024: $1,053 · 2025: $5,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,828 · Travel and Lodging: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,828.37 |
| Travel and Lodging | $1,828.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,982.88 | 2021-2025 | Proclaim, Eterna, Ionicrf |
| Globus Medical, INC. | $1,676.83 | 2025 | Senza, Omnia |
| Nevro Corp. | $917.73 | 2019-2024 | Senza, Vyrsa V1 |
| Medtronic, INC. | $657.62 | 2021-2025 | Inceptiv, Percept PC Brainsense, Intellis Adaptivestim |
| Nalu Medical, INC. | $574.70 | 2025 | Nalu Neurostimulation System |
| Scilex Pharmaceuticals INC. | $388.39 | 2019-2022 | |
| Amgen INC. | $295.53 | 2019-2021 | |
| Biotronik Nro, INC. | $275.75 | 2025 | Prospera |
| Pacira Therapeutics, INC. | $160.60 | 2020-2021 | |
| Microtransponder, INC. | $130.89 | 2023 | |
| Medtronic USA, INC. | $117.13 | 2019 | |
| Daiichi Sankyo INC. | $94.32 | 2019 | |
| Abbvie INC. | $68.01 | 2024-2025 | |
| Redhill Biopharma INC. | $41.52 | 2020 | |
| Merz Pharmaceuticals, LLC | $38.50 | 2024 | Xeomin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.53 | 2025 | Relistor |
| Spr Therapeutics, INC | $26.36 | 2024 | Sprint Pns System |
| Bioventus LLC | $20.88 | 2020 | |
| Paratek Pharmaceuticals, INC. | $19.79 | 2025 | Nuzyra |
| Ermi LLC | $18.74 | 2024 | |
| Averitas Pharma INC. | $17.81 | 2025 | Qutenza |
| Depuy Synthes Sales INC. | $16.11 | 2020 | |
| Radius Health, INC. | $15.29 | 2019 | |
| Biodelivery Sciences International, INC. | $14.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manouchehr Refaeian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.